Founded in 1890 as the first manufacturer of electric fans in North America, Emerson Electric has become a leading industrial automation player through the acquisition of established brands... Show more
Emerson Electric has completed a multi-year transformation into a focused global automation and industrial software leader. Following the full acquisition of AspenTech and the $8.2 billion purchase of National Instruments, the company now operates through five streamlined segments: Control Systems & Software, Test & Measurement, Sensors, Final Control, and Safety & Productivity. This structure consolidates its leadership across the automation technology stack — from intelligent field devices to enterprise-level software and AI (artificial intelligence) platforms.
Emerson holds either the first or second market share in a broad range of process automation categories, and the competitive landscape remains fragmented enough to suggest further organic and inorganic runway. The company's competitive moat rests on deep installed-base relationships, high customer switching costs, and a portfolio that integrates sensors, valves, control systems, and predictive analytics into a single ecosystem. The "Project Beyond" initiative — a software-defined, OT-ready (operational technology) digital platform — aims to further differentiate Emerson by simplifying how industrial customers deploy AI and data management solutions without replacing legacy infrastructure.
However, the business is not without structural risks. Margins in the newly restructured Intelligent Devices group remain exposed to tariff volatility, FX translation effects, and uneven demand in certain end markets, particularly in Europe and China. Additionally, Emerson's revenue growth trajectory, while accelerating, is expected to trail the broader industrial automation sector's projected growth rate, according to some analyst consensus estimates.
Several catalysts could reshape the investment narrative for Emerson Electric over the coming quarters.
Earnings momentum and backlog conversion. The company guided for approximately 4.5% net sales growth in fiscal 2026, with adjusted EPS (earnings per share) between $4.79 and $4.89. More critically, management and analysts point to a sharp growth pickup in the second half of fiscal 2026 as large, long-cycle projects in power generation, LNG infrastructure, semiconductor fabrication, and aerospace & defense finally move from the order book to recognized revenue. Emerson reported 9% order growth in Q1 fiscal 2026, reinforcing this thesis.
Analyst rating upgrades and target revisions. In July 2026, J.P. Morgan analyst Chigusa Katoku upgraded Emerson to a Buy rating with a $157 price target, citing the backlog conversion story and improving process-industry macro conditions. Bernstein initiated coverage with an Outperform rating and a $175 target, while D.A. Davidson launched coverage at Neutral with a $145 target. The current consensus rating among 28 analysts is Overweight, with an average price target of roughly $152 to $154, implying a potential upside from mid-2026 trading levels. However, some caution persists — Wells Fargo downgraded EMR to Equal-Weight in late 2025, and near-term earnings estimates have seen modest downward revisions.
Middle East recovery optionality. Emerson has assumed a roughly $100 million revenue headwind in the second half due to regional tensions, but J.P. Morgan notes that an equal amount of repair and restart work could materialize over six quarters if de-escalation occurs — a potential upside not yet reflected in guidance.
Capital allocation execution. Emerson's commitment to return $10 billion to shareholders through dividends and buybacks by 2028 signals confidence in sustained free cash flow generation. The company raised its quarterly dividend by more than 5% in late 2025, extending a remarkable 55-year streak of annual dividend increases.
Emerson's trajectory is tightly linked to global industrial capital expenditure (capex) cycles. Encouragingly, rig counts and refinery capex forecasts have been revised upward, suggesting the process-industry cycle may be turning favorable after a period of uneven demand. The power end market — driven by grid modernization, data center expansion, and electrification — has emerged as a particularly robust demand driver, with Emerson's Final Control and Sensors businesses benefiting directly.
On the other hand, macroeconomic crosscurrents remain significant. Interest rates, while off their cycle peaks, are not yet falling rapidly enough across all major economies to meaningfully accelerate industrial project approvals. Europe's manufacturing sector continues to show softness, and China's recovery has been inconsistent. Tariff policy uncertainty — especially around inputs that affect Emerson's Intelligent Devices cost structure — could continue to weigh on margins even as revenue growth accelerates.
The geopolitical landscape also matters. Beyond the Middle East, any escalation of trade restrictions or conflict could disrupt Emerson's global supply chain and customer demand patterns. Conversely, rising defense spending in NATO countries and ongoing energy-security priorities are structural tailwinds for Emerson's automation solutions in aerospace & defense and LNG infrastructure.
Investors seeking to anticipate future price movements in Emerson Electric may find value in Tickeron's Trend Prediction Engine. This AI-powered forecasting tool analyzes market data to help traders identify whether a stock, ETF (exchange-traded fund), or other tradable instrument may be poised for a bullish, bearish, or sideways trajectory over the coming week or month. Designed for both active traders and longer-term investors, the Trend Prediction Engine evaluates developing trends, potential breakouts or reversals, and consolidations across a broad universe of instruments. The platform organizes predictions into searchable categories, provides historical context for each signal, and supports alert-based functionality so users can monitor evolving conditions efficiently. Exploring the Trend Prediction Engine can complement traditional fundamental analysis when assessing the near-term direction of stocks like Emerson Electric.
Looking toward the remainder of 2026 and beyond, Emerson's long-term investment case revolves around several structural themes.
Market expansion in high-growth verticals. Emerson has identified power, LNG, life sciences, semiconductors, and aerospace & defense as its primary growth verticals. These end markets benefit from secular drivers — energy transition investment, pharmaceutical manufacturing reshoring, chip fab construction, and rising global defense budgets — that are largely independent of short-term economic fluctuations. The company's 2025 Investor Conference set a target of $21 billion in net sales by fiscal 2028, representing a roughly 5% organic compound annual growth rate (CAGR).
Margin expansion and cost structure evolution. Emerson is targeting 30% adjusted segment EBITA (earnings before interest, taxes, and amortization) margin by 2028, implying approximately 240 basis points of expansion from current levels. Price realization, operational excellence programs, and acquisition synergies — particularly from the AspenTech and National Instruments integrations — are expected to drive this improvement. The shift toward higher-margin software and recurring revenue streams within the Control Systems & Software segment is a critical component of this margin narrative.
Technology transitions and competitive positioning. The industrial automation industry is undergoing a generational technology shift toward software-defined, AI-enabled systems. Emerson's "Project Beyond" platform is a direct bet on this transition, aiming to unify the fragmented OT landscape under a single, secure, data-centric architecture. Success here could materially expand Emerson's addressable market and deepen its competitive moat. Conversely, execution risk remains: integrating large-scale software acquisitions, scaling AI capabilities, and persuading risk-averse industrial customers to adopt new architectures are non-trivial challenges.
Capital allocation priorities. With $12 billion in projected cumulative free cash flow from fiscal 2026 through 2028, Emerson has significant flexibility. The company's stated preference is to prioritize shareholder returns, but bolt-on M&A (mergers and acquisitions) in complementary automation and software adjacencies could also accelerate growth. The company's recent addition to the Russell 1000 Value-Defensive and Russell 1000 Defensive indexes in June 2026 underscores its evolving profile as a more resilient, cash-generative industrial enterprise.
Consensus analyst expectations project EPS growth from approximately $5.97 in fiscal 2025 toward $7.09 by fiscal 2027. While near-term earnings estimates have seen modest trimming, the longer-term outlook remains supported by Emerson's exposure to durable secular trends and its disciplined approach to capital allocation. Investors will be closely watching whether the backlog conversion story delivers as promised — and whether "Project Beyond" can translate technological ambition into sustained competitive advantage.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
a developer of process controls systems, valves and analytical instruments
Industry IndustrialMachinery
A.I.dvisor indicates that over the last year, EMR has been closely correlated with ROK. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if EMR jumps, then ROK could also see price increases.
| Ticker / NAME | Correlation To EMR | 1D Price Change % | ||
|---|---|---|---|---|
| EMR | 100% | +0.79% | ||
| ROK - EMR | 76% Closely correlated | +1.93% | ||
| AME - EMR | 69% Closely correlated | +0.71% | ||
| LECO - EMR | 69% Closely correlated | +4.43% | ||
| KMT - EMR | 64% Loosely correlated | +1.95% | ||
| NDSN - EMR | 64% Loosely correlated | +0.86% | ||
More | ||||
| Ticker / NAME | Correlation To EMR | 1D Price Change % |
|---|---|---|
| EMR | 100% | +0.79% |
| EMR (7 stocks) | 79% Closely correlated | +1.19% |
| Producer Manufacturing (352 stocks) | 11% Poorly correlated | -0.00% |
EMR saw its Momentum Indicator move above the 0 level on July 21, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for EMR just turned positive on July 22, 2026. Looking at past instances where EMR's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
EMR moved above its 50-day moving average on July 23, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for EMR crossed bullishly above the 50-day moving average on July 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EMR advanced for three days, in of 335 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for EMR moved out of overbought territory on July 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
EMR broke above its upper Bollinger Band on July 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EMR entered a downward trend on July 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.134) is normal, around the industry mean (5.857). P/E Ratio (34.681) is within average values for comparable stocks, (59.887). Projected Growth (PEG Ratio) (2.089) is also within normal values, averaging (2.036). Dividend Yield (0.015) settles around the average of (0.019) among similar stocks. P/S Ratio (4.617) is also within normal values, averaging (137.659).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.